Patients’ characteristics at time of rituximab administration (n = 30)
| Characteristic . | No. . | % . |
|---|---|---|
| Persistent undetectable ADAMTS13 activity after TTP episode | 10 | 33 |
| Occurrence of undetectable ADAMTS13 activity during follow-up | 20 | 67 |
| Age, y | ||
| Median | 38 | |
| Range | 30-44 | |
| Female | 19 | 63 |
| White (North African patients included) | 25 | 83 |
| Characteristic . | No. . | % . |
|---|---|---|
| Persistent undetectable ADAMTS13 activity after TTP episode | 10 | 33 |
| Occurrence of undetectable ADAMTS13 activity during follow-up | 20 | 67 |
| Age, y | ||
| Median | 38 | |
| Range | 30-44 | |
| Female | 19 | 63 |
| White (North African patients included) | 25 | 83 |
Results are given as medians (25th to 75th percentile) for quantitative variables and as number (percentage) for qualitative variables.